In a recent double-blind prospective trial (SORMAIN) (86), 83 transplanted FLT3-ITD adult AML patients were randomized to receive either maintenance sorafenib (n = 43, up to 400 mg twice daily) or placebo (n = 40) started between days 60 and 100 after transplant for up to 24 months. Here, FLT3 is linked to acute myeloid leukemia.